For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Semaglutide

Also known as: Semaglutide (GLP-1 agonist)

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.

Where to buy · live market data

Who's worth your money for Semaglutide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (96) of 6 scored sellers

$3.00/mg

$60.00 · 20mg · 99.2% purity

Best value

Lowest $/mg among scored sellers

$1.00/mg

$10.00 · 10mg

no COAs yet

Most tested

11 independent COAs on file

$9.00/mg

$90.00 · 10mg · 99.9% purity

Average price

$6.70/mg

Sellers

23

45-day trend

+4.5%

20 of 23 sellers have a current price· 14 stale hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Semaglutide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Semaglutide

CAS

910463-68-2

Molecular formula

C187H291N45O59

Typical dose range

0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks

Half-life

~7 days

Independent evidence

COAs for Semaglutide

196 third-party tests across 31 vendors. Each card links to the full report.

All 196 COAs for Semaglutide →
Measured purity 99.0%–100.0% across 121 COAs
Measured purity over time
✓ Vendor-published
99.66 %
Nov 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Ignite Peptides· batch SM20392

COA on file
Aggregated · 3rd-party listing
99.95 %
Aug 2026
Freedom Diagnostics Moderate

For

Semaglutide

by VoriLabs· batch SEMA_2608-A

Aggregated · 3rd-party listing
99.84 %
Aug 2026
ILS Labs Strong

For

Semaglutide

by Velora Biolabs· batch VBL-SM20-1

Aggregated · 3rd-party listing
99.85 %
Aug 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Peptide Plugs· batch 189-02-DK

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Semaglutide

by VoriLabs· batch VoriLabs SEMA-2607-C

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Semaglutide

by VoriLabs· batch VoriLabs SEMA-2607-B

✓ Vendor-published
99.74 %
Jul 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1007112026-04

COA on file
Aggregated · 3rd-party listing
99.77 %
Jul 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Synthesis Peptides· batch 1G10826

Aggregated · 3rd-party listing
99.76 %
Jul 2026
ILS Labs Strong

For

Semaglutide

by Hydro Research Peptides· batch HR-2026-7341

Aggregated · 3rd-party listing
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Semaglutide

by Longeva· batch B-2026-SEMA-5-001

✓ Vendor-published
99.94 %
Jun 2026
TrustPointe Analytics Moderate

For

Semaglutide

by Peptide Partners· batch SPL-4149

COA on file
Aggregated · 3rd-party listing
99.07 %
Jun 2026
ILS Labs Strong

For

Semaglutide

by Peptide Plugs· batch 125-01-SM

Aggregated · 3rd-party listing
99.90 %
Jun 2026
Prime Analytical Laboratories, LLC

For

Semaglutide

by Soma Peptides· batch SEV052657

Aggregated · 3rd-party listing
99.80 %
May 2026
Vanguard Laboratory Strong

For

Semaglutide

by Certified Peptides· batch 260518SG53

Aggregated · 3rd-party listing
99.75 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

✓ Vendor-published
99.63 %
May 2026
Janoshik Analytical Limited

For

Semaglutide

by EZ Peptides· batch EZP-1P1005102026-03

COA on file
Aggregated · 3rd-party listing
99.91 %
May 2026
Freedom Diagnostics Moderate

For

Semaglutide

by Blank Peptides· batch GS10-052026-4

Aggregated · 3rd-party listing
99.23 %
May 2026
Horizon Analytical

For

Semaglutide

by Pepsgpt· batch P-2885342-P

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3022026SM

Aggregated · 3rd-party listing
99.75 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 3142026SM

Aggregated · 3rd-party listing
99.17 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Semaglutide

by Prime Peptides· batch 2242026SM

✓ Vendor-published
99.96 %
Apr 2026
Kovera Labs

For

ION-1S

by Ion Peptide· batch ION1S20-04172026

COA on file
Aggregated · 3rd-party listing
99.70 %
Apr 2026
BTLabs Moderate

For

Semaglutide

by Vertex Labs· batch SM0000038

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

Semaglutide

by OROS Research· batch OR-LPGLPS10-426-B3

Research depth

23 citations indexed for Semaglutide

All research on Semaglutide →

rct · Ongoing

Semaglutide for the Treatment of Cannabis Use Disorder

The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1. Does semaglutide effect reactivity to cannabis-related cues? 2.

Study · 2026

Oral Semaglutide and the Kidney: Promise, Limitations, and the Road Ahead

Study · 2026

Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance

Purpose To evaluate how confounding by indication and notoriety bias shape the apparent semaglutide-panic attack signal in the FDA Adverse Event Reporting System (FAERS) and to interpret this signal using an evidence-triangulation framework integrating randomized and observational studies.

cohort · 2026

Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS

Background Semaglutide and tirzepatide are widely used for type 2 diabetes and obesity, but comparative post-marketing safety data remain limited.

Study · 2026

Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide

Background Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation.

case-report · 2026

Starvation-associated high-anion gap metabolic acidosis following short-term oral semaglutide use: A case report

Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for weight reduction beyond its approved indications. We report a case of starvation-associated euglycemic ketoacidosis in a previously healthy, nondiabetic young woman following short-term oral semaglutide use.